MedTrace Logo

MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease

NCT04116242 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 277

Last updated 2024-06-25

No results posted yet for this study

Summary

This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, acute-on-chronic liver failure (ACLF)) and in comparison to patients with acute liver failure and to healthy controls.

Conditions

  • Liver Disease
  • Cirrhosis of the Liver
  • Acute-On-Chronic Liver Failure
  • Liver Failure

Interventions

OTHER

blood sampling for research purpose

blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place

OTHER

clinical data collection

clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time

OTHER

Health-related Questionnaires

Health-related Questionnaires (Questionnaire\_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)

OTHER

Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)

Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Christine Bernsmeier, PD Dr. Dr. · Universitätsspital Basel, Departement Biomedizin, Gastroenterologie und Hepatologie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-27
Primary Completion
2024-06-10
Completion
2024-06-10

Countries

  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04116242 on ClinicalTrials.gov